Lifecycle Management and Generic Cost Reduction: A Look at the Apixaban Market Economic Outlook
The Apixaban Market Economic Outlook is characterized by a high-value branded phase that is transitioning toward a high-volume, lower-cost generic phase. During the branded period, the market's economic strength is derived from the high therapeutic value it delivers—preventing costly, debilitating strokes—which justifies premium pricing in health economic terms. Payers recognize...
0 Commentarii 0 Distribuiri 246 Views 0 previzualizare